Bill > S652

This bill aims to regulate communications about prescription drugs on social media by establishing new rules and penalties for false or misleading information. The legislation would create civil penalties for social media influencers and healthcare providers who make knowingly false or incomplete statements about prescription drugs, particularly those made with financial incentives. The bill defines "false or misleading communications" as advertisements on social media platforms that contain inaccurate statements, omit important safety information, or fail to provide a brief summary of side effects and drug effectiveness. Social media influencers are specifically defined as individuals with perceived credibility who promote products to their audience. The bill requires the Secretary of Health and Human Services to issue guidance on determining what constitutes false communication within 180 days and mandates reporting of payments between drug manufacturers, healthcare providers, and influencers. Additionally, the legislation establishes market surveillance activities for prescription drug advertising, including potential use of artificial intelligence to monitor social media platforms, and authorizes $15 million annually from 2025-2029 to support these efforts. The goal is to protect patients from potentially dangerous or misleading drug information by increasing transparency and accountability in digital medical communications.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/652/all-info